Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou(Tongji University), Changxuan You(Southern Medical University), Jian-An Huang(Soochow University), Yi Luo(Kunming Institute of Botany), Chengping Hu(Central South University), Lei Chen(Zhuzhou Central Hospital), Li Zhang(Jinan Stomatological Hospital), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunhong Hu(Central South University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Songwen Zhou(Tongji University), Ming Ye(Florida State University), Jifeng Feng(Zhejiang Cancer Hospital), Yiping Zhang(Henan Normal University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Shucai Zhang(Northeastern University), Shun Lu, Xiaoqing Liu(Chinese PLA General Hospital), Gongyan Chen(Harbin Medical University), Jun Ma, Qingyu Xiu(Second Military Medical University), Shengxiang Ren(Tongji University)
Unknown
March 8, 2011
Cited by 5

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k